Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2008-001024-31 | EudraCT Number | ||
| 08/S0501/31 | Other Identifier | REC Reference | |
| 09/800/03 | Other Grant/Funding Number | NIHR EME |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Dundee | OTHER |
| National Institute for Health Research, United Kingdom | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this trial is to determine whether iodide supplementation of neonates born under 31 weeks gestation improves neurodevelopment measured at two years of age.
Iodine is essential for the synthesis of thyroxine, and thyroxine is essential for normal brain development in utero and for the first 2-3 years of life. The recommended iodine intake in parenteral nutrition regimens is 1 μg/kg/day and commercially available parenteral solutions for infants reflect these recommendations. In the absence of other iodine sources, infants are vulnerable to negative iodine balance and insufficiency. As many preterm infants are fed parenterally for prolonged periods with solutions which have been shown to be iodine-deficient, the I2S2 Trial was designed as a UK multicentre randomised controlled trial to establish whether iodine supplementation of preterm infants benefits neurodevelopment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Iodine | Experimental | This is the hypothetical active arm |
|
| Placebo | Placebo Comparator | this is the hypothetical placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| sodium iodide | Drug | sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Appreciable neurodevelopmental impairment at 2 years corrected age. As measured by the three main domains of the Bayley III score: i.e. cognitive score, language composite score and motor composite score. | P ≤0.05 will be the level used to indicate statistical significance.Deaths and those infants with severe neurodevelopment disability will be scored 55 in the cognitive domain, 46 in the motor domain and 47 in the language domain. The primary outcome will be ordered as cognitive score, motor composite score and language composite score in all results presented. | at 2 years corrected age |
| Measure | Description | Time Frame |
|---|---|---|
| Blood levels of T4, TSH and TBG on day 7, 14, 28 and 34 weeks corrected age. | 2 years corrected age | |
| Neurodevelopment impairment as a composite of death or a Bayley III score of <85 in any of the score's three main subsets domains: cognitive, language and motor composites. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Fiona Williams, Dr | University of Dundee | Study Director |
| Peter Brocklehurst, Professor | UCL | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ninewells Hospital and Medical School | Dundee | Tayside | DD1 9SY | United Kingdom | ||
| Royal Maternity Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24576827 | Background | Williams F, Hume R, Ogston S, Brocklehurst P, Morgan K, Juszczak E; I2S2 team. A summary of the iodine supplementation study protocol (I2S2): a UK multicentre randomised controlled trial in preterm infants. Neonatology. 2014;105(4):282-9. doi: 10.1159/000358247. Epub 2014 Feb 27. |
| Label | URL |
|---|---|
| Supports programme of work | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sodium Chloride | Drug | Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation |
|
| 2 years corrected age |
| Neurodevelopmental impairment assessed as a difference between the iodine supplemented and placebo groups in each of the four subset scores of the Bayley III i.e. receptive communication, expressive communication, fine motor or gross motor. | 2 years corrected age |
| Type and severity of illness: necrotising enterocolitis | Type and severity of illness: necrotising enterocolitis | 2 years corrected age |
| Type and severity of illness:persistent ductus arteriosus | Type and severity of illness:persistent ductus arteriosus | 2 years corrected age |
| Type and severity of illness: respiratory distress | Type and severity of illness: respiratory distress | 2 years corrected age |
| Type and severity of illness:chronic lung disease (need for oxygen at 36 weeks corrected age) | Type and severity of illness: chronic lung disease (need for oxygen at 36 weeks corrected age) | 2 years corrected age |
| Cranial ultrasound changes | cranial ultrasound changes | 2 years corrected age |
| Acquired infection | Acquired infection as indicated by medical notes during neonatal period | 2 years corrected age |
| Cranial ultrasound changes | Type and severity of illness: necrotising enterocolitis, persistent ductus arteriosus, respiratory distress , chronic lung disease (need for oxygen at 36 weeks corrected age), cranial ultrasound changes, acquired infection; hearing and vision impairment; postnatal drug use (e.g. diamorphine, dexamethasone, dopamine, caffeine and indomethacin); nutritional status; BAPM level of care; highest recorded bilirubin levels; and death - immediate and underlying causes. | 2 years corrected age |
| Hearing and vision impairment | Hearing and vision impairment as indicated by parental questionnaire | 2 years corrected age |
| Postnatal drug use | diamorphine, dexamethasone, dopamine, caffeine and indomethacin | 2 years corrected age |
| Nutritional status | Nutritional status collected on postnatal day 7, 14, 28 and 34 corrected weeks (as indicated by neonatal drug chart | 2 years corrected age |
| BAPM level of care | BAPM level of care | 2 years corrected age |
| Highest recorded bilirubin levels | highest recorded bilirubin levels; and death - immediate and underlying causes. | 2 years corrected age |
| Death - immediate and underlying causes. | Death - immediate and underlying causes. | 2 years corrected age |
| Belfast |
| BT12 6BB |
| United Kingdom |
| Heartlands Hospital | Birmingham | B9 5SS | United Kingdom |
| University Hospital Coventry | Coventry | CV2 2DX | United Kingdom |
| Derbyshire Childrens Hospital | Derby | DE22 3NE | United Kingdom |
| Princess Royal Maternity Hospital | Glasgow | G31 2ER | United Kingdom |
| Southern General Hospital | Glasgow | G51 4TF | United Kingdom |
| Crosshouse Hospital | Kilmarnock | KA2 0BE | United Kingdom |
| Leicester Royal Infirmary | Leicester | LE1 5WW | United Kingdom |
| Altnagelvin Area Hospital | Londonderry | BT47 6SB | United Kingdom |
| James Cook University Hospital | Middlesbrough | TS4 3BW | United Kingdom |
| Royal Victoria Infirmary | Newcastle upon Tyne | United Kingdom |
| Nottingham City Hospital | Nottingham | NG5 1PW | United Kingdom |
| Queen's Medical Centre | Nottingham | NG7 2UH | United Kingdom |
| Royal Berkshire Hospital | Reading | RG1 5AN | United Kingdom |
| Jessops Wing Hospital | Sheffield | S10 2SF | United Kingdom |
| University Hospital of North Tees | Stockton-on-Tees | United Kingdom |
| Sunderland City Hospitals | Sunderland | SR4 7TP | United Kingdom |
| Wishaw General Hospital | Wishaw | ML2 0DP | United Kingdom |
| ID | Term |
|---|---|
| D012974 | Sodium Iodide |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D007454 | Iodides |
| D017613 | Iodine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
Not provided
Not provided